Greenbrook TMS Announces Dates for Its Fourth Quarter and Year End 2021 Financial Results

Rhea-AI Summary

Greenbrook TMS Inc. (NASDAQ: GBNH) will announce its 2021 fourth quarter and year-end financial results after market hours on March 31, 2022. A conference call is scheduled for April 1, 2022, at 10:00 a.m. ET, where CEO Bill Leonard and CFO Erns Loubser will discuss the results. Greenbrook operates 148 treatment centers across the U.S., specializing in FDA-cleared Transcranial Magnetic Stimulation (TMS) therapy for Major Depressive Disorder, having provided over 730,000 treatments to more than 20,000 patients.

Positive

• Leading provider of Transcranial Magnetic Stimulation therapy with 148 treatment centers.
• Delivered over 730,000 TMS treatments to over 20,000 patients, indicating strong market presence.

Negative

• None.

TORONTO--(BUSINESS WIRE)-- Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (“Greenbrook” or the “Company”), will release its 2021 fourth quarter and year end operational and financial results after market hours on March 31, 2022.

FOURTH QUARTER AND YEAR END 2021 CONFERENCE CALL DETAILS:

Bill Leonard, President and Chief Executive Officer, and Erns Loubser, Chief Financial Officer, will host a conference call at 10:00 a.m. (Eastern Time) on April 1, 2022 to discuss the financial results for the quarter.

Dial in Numbers:

Toll Free North America: (866) 521-4909
Toronto: (647) 427-2311

Webcast:

For more information or to listen to the call via webcast, please visit:
www.greenbrooktms.com/investors/events.htm

For those that plan on accessing the conference call or webcast, please allow ample time prior to the call time.

Conference Call Replay:

Toll Free (North America): (800) 585-8367
Toronto: (416) 621-4642
Conference ID: 6080804

The conference call replay will be available from 1:00 p.m. ET on April 1, 2022, until 11:59 p.m. ET on May 1, 2022.

About Greenbrook TMS Inc.

Operating through 148 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 730,000 TMS treatments to over 20,000 patients struggling with depression.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220224005732/en/

Glen Akselrod

Investor Relations

Greenbrook TMS Inc.



Contact Information:

investorrelations@greenbrooktms.com

1-855-797-4867

Source: Greenbrook TMS Inc.

FAQ

When will Greenbrook TMS Inc. release its 2021 financial results?

Greenbrook TMS Inc. will release its 2021 financial results after market hours on March 31, 2022.

What time is the Greenbrook TMS conference call for Q4 and year-end 2021 results?

The conference call is scheduled for April 1, 2022, at 10:00 a.m. ET.

What is Greenbrook TMS Inc.'s ticker symbol?

Greenbrook TMS Inc.'s ticker symbol is GBNH on NASDAQ.

How many treatment centers does Greenbrook operate?

Greenbrook operates 148 treatment centers across the United States.

What type of therapy does Greenbrook provide?

Greenbrook provides Transcranial Magnetic Stimulation (TMS) therapy for Major Depressive Disorder.